Palo Alto Investors’s Cytokinetics CYTK Stock Holding History

Palo Alto Investors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.12M	Buy	+32,195	New	+$2.05M	0.32%	36
2024 Q3	–	Sell	-111,717	Closed	-$6.05M	–	46
2024 Q2	$6.05M	Hold	111,717	–	–	0.7%	22
2024 Q1	$7.83M	Hold	111,717	–	–	0.88%	22
2023 Q4	$9.33M	Hold	111,717	–	–	0.84%	20
2023 Q3	$3.29M	Hold	111,717	–	–	0.31%	21
2023 Q2	$3.64M	Hold	111,717	–	–	0.29%	21
2023 Q1	$3.93M	Hold	111,717	–	–	0.33%	19
2022 Q4	$5.12M	Hold	111,717	–	–	0.44%	18
2022 Q3	$5.41M	Hold	111,717	–	–	0.43%	22
2022 Q2	$4.39M	Hold	111,717	–	–	0.38%	24
2022 Q1	$4.11M	Sell	111,717 -11,969	-10%	-$425K	0.32%	25
2021 Q4	$5.64M	Hold	123,686	–	–	0.36%	24
2021 Q3	$4.42M	Hold	123,686	–	–	0.27%	27
2021 Q2	$2.45M	Hold	123,686	–	–	0.13%	31
2021 Q1	$2.88M	Hold	123,686	–	–	0.16%	31
2020 Q4	$2.57M	Hold	123,686	–	–	0.13%	32
2020 Q3	$2.68M	Hold	123,686	–	–	0.15%	31
2020 Q2	$2.92M	Hold	123,686	–	–	0.18%	25
2020 Q1	$1.46M	Hold	123,686	–	–	0.12%	26
2019 Q4	$1.31M	Hold	123,686	–	–	0.07%	29
2019 Q3	$1.41M	Hold	123,686	–	–	0.09%	29
2019 Q2	$1.39M	Hold	123,686	–	–	0.07%	31
2019 Q1	$1M	Hold	123,686	–	–	0.04%	32
2018 Q4	$782K	Hold	123,686	–	–	0.04%	31
2018 Q3	$1.22M	Hold	123,686	–	–	0.05%	31
2018 Q2	$1.03M	Hold	123,686	–	–	0.04%	31
2018 Q1	$891K	Hold	123,686	–	–	0.04%	32
2017 Q4	$1.01M	Hold	123,686	–	–	0.04%	33
2017 Q3	$1.79M	Hold	123,686	–	–	0.08%	31
2017 Q2	$1.5M	Hold	123,686	–	–	0.07%	31
2017 Q1	$1.59M	Hold	123,686	–	–	0.08%	30
2016 Q4	$1.5M	Hold	123,686	–	–	0.09%	30
2016 Q3	$1.14M	Hold	123,686	–	–	0.07%	36
2016 Q2	$1.17M	Hold	123,686	–	–	0.09%	37
2016 Q1	$872K	Hold	123,686	–	–	0.07%	40
2015 Q4	$1.29M	Hold	123,686	–	–	0.07%	39
2015 Q3	$827K	Hold	123,686	–	–	0.04%	42
2015 Q2	$831K	Hold	123,686	–	–	0.04%	43
2015 Q1	$839K	Hold	123,686	–	–	0.04%	43
2014 Q4	$991K	Hold	123,686	–	–	0.06%	42
2014 Q3	$435K	Hold	123,686	–	–	0.03%	42
2014 Q2	$591K	Sell	123,686 -123,500	-50%	-$754K	0.04%	41
2014 Q1	$2.35M	Buy	247,186 +14,378	+6%	+$130K	0.19%	30
2013 Q4	$1.51M	Sell	232,808 -28,736	-11%	-$189K	0.14%	30
2013 Q3	$1.98M	Hold	261,544	–	–	0.21%	27
2013 Q2	$3.03M	Buy	+261,544	New	+$2.06M	0.36%	25

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Palo Alto Investors's CYTK Position: Q1 2026 in Review

Palo Alto Investors opened a new position in Cytokinetics (CYTK) in Q1 2026: 32,195 shares worth $2.12M. The stake represents 0.32% of the portfolio and ranks #36 among its holdings. This is a return to the name: Palo Alto Investors previously reported a position in CYTK as recently as Q2 2024.

Palo Alto Investors first reported a position in CYTK in Q2 2013 and has held it in 46 quarters since. The position peaked at $9.33M in Q4 2023. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Palo Alto Investors held 32,195 shares of Cytokinetics worth $2.12M as of Q1 2026.
Cytokinetics was a new Palo Alto Investors position in Q1 2026.
Cytokinetics made up 0.32% of Palo Alto Investors's portfolio in Q1 2026, its #36 holding.
Palo Alto Investors first reported a position in Cytokinetics in Q2 2013 and has held it in 46 quarters since.
Palo Alto Investors's Cytokinetics position peaked at $9.33M in Q4 2023.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.